Tests prasinezumab infusions against placebo in early Parkinson's disease
Tests prasinezumab, given into a vein, in adults with early-stage Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Key facts
- Where
- Changhua County, North Dist., Tainan, Taipei, and Taoyuan City, TaiwanSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage Parkinson's disease who take levodopa alone and have been on a stable dose. It compares prasinezumab given by IV with placebo.
- Age
- 50 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Early-stage idiopathic Parkinson's disease, Hoehn and Yahr Stage 1 or 2 off medication, with an MDS-UPDRS Part IV score of 0.
- Earlier treatment
- Has received monotherapy treatment (stable symptomatic levodopa alone).
Main reasons for not taking part
- Pregnant or breastfeeding, or planning a pregnancy during the study
- A parkinsonian syndrome other than idiopathic Parkinson's disease
- A significant neurologic disease other than Parkinson's disease
- Chronic uncontrolled high blood pressure
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
- Has a doctor told you that you have a different condition with similar signs, such as multiple system atrophy or progressive supranuclear palsy?
- Which medicine do you take for Parkinson's disease now?
- Are you pregnant, breastfeeding, or planning a pregnancy?
Source: NCT07174310, who can take part
Where in Taiwan
- Changhua Christian HospitalChanghua County, TaiwanTaking people
- China Medical University HospitalNorth Dist., TaiwanTaking people
- National Cheng Kung University HospitalTainan, TaiwanTaking people
- National Taiwan University HospitalTaipei, TaiwanTaking people
- Taipei Veterans General HospitalTaipei, TaiwanTaking people
- Chang Gung Memorial Hospital LinkouTaoyuan City, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07174310EU 2025-522683-32-00
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Inclusion: Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2; Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria; Has received monotherapy treatment; An MDS-UPDRS Part IV score of 0 at screening and prior to randomization; Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization; Agreement to adhere to the contraception requirements.
Exclusion: Medical history indicating a parkinsonian syndrome other than idiopathic PD; Diagnosis of a significant neurologic disease other than PD; Chronic uncontrolled hypertension; Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required.